Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease

S. K. Libutti, P. L. Choyke, H. R. Alexander, G. Glenn, D. L. Bartlett, B. Zbar, I. Lubensky, S. A. McKee, E. R. Maher, W. M. Linehan, M. M. Walther, G. Akerstrom, J. Chabot

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Background. Patients with von Hippel-Lindau disease (VHL) may develop pancreatic neuroendocrine tumors (PNETs), which can behave in a malignant fashion. We prospectively evaluated size criteria for resection of lesions and the role of genotype/phenotype analysis of germline VHL mutations in predicting clinical course. Methods. From December 1988 through December 1999 we screened 389 patients with VHL. The diagnosis of PNET was made by pathologic analysis of tissues or by radiographic appearance. Germline mutations were determined by quantitative Southern blotting, fluorescence in situ hybridization and complete gene sequencing. Results. Forty-four patients with PNETs have been identified; 25 have undergone surgical resection, 5 had metastatic disease, and 14 are being monitored. No patient who has undergone resection based on tumor size criteria has developed metastases. Patients with PNETs were more likely to have missense mutations (58%), and 4 of 5 patients (80%) with metastatic disease had mutations in exon 3 compared with 18 of 39 (46%) patients without metastatic disease. Conclusions. Imaging for detection and surgical resection based on size criteria have resulted in the successful management of VHL patients with PNETs. Analysis of germline mutations may help identifiy patients at risk for PNET and which patients may benefit from surgical intervention.

Original languageEnglish (US)
Pages (from-to)1022-1028
Number of pages7
JournalSurgery
Volume128
Issue number6
StatePublished - 2000
Externally publishedYes

Fingerprint

von Hippel-Lindau Disease
Neuroendocrine Tumors
Germ-Line Mutation
Mutation
Missense Mutation
Southern Blotting
Fluorescence In Situ Hybridization
Exons
Genotype
Neoplasm Metastasis

ASJC Scopus subject areas

  • Surgery

Cite this

Libutti, S. K., Choyke, P. L., Alexander, H. R., Glenn, G., Bartlett, D. L., Zbar, B., ... Chabot, J. (2000). Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery, 128(6), 1022-1028.

Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. / Libutti, S. K.; Choyke, P. L.; Alexander, H. R.; Glenn, G.; Bartlett, D. L.; Zbar, B.; Lubensky, I.; McKee, S. A.; Maher, E. R.; Linehan, W. M.; Walther, M. M.; Akerstrom, G.; Chabot, J.

In: Surgery, Vol. 128, No. 6, 2000, p. 1022-1028.

Research output: Contribution to journalArticle

Libutti, SK, Choyke, PL, Alexander, HR, Glenn, G, Bartlett, DL, Zbar, B, Lubensky, I, McKee, SA, Maher, ER, Linehan, WM, Walther, MM, Akerstrom, G & Chabot, J 2000, 'Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease', Surgery, vol. 128, no. 6, pp. 1022-1028.
Libutti SK, Choyke PL, Alexander HR, Glenn G, Bartlett DL, Zbar B et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery. 2000;128(6):1022-1028.
Libutti, S. K. ; Choyke, P. L. ; Alexander, H. R. ; Glenn, G. ; Bartlett, D. L. ; Zbar, B. ; Lubensky, I. ; McKee, S. A. ; Maher, E. R. ; Linehan, W. M. ; Walther, M. M. ; Akerstrom, G. ; Chabot, J. / Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. In: Surgery. 2000 ; Vol. 128, No. 6. pp. 1022-1028.
@article{21184a6f6a8f4871a0a937f7df5eb1a4,
title = "Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease",
abstract = "Background. Patients with von Hippel-Lindau disease (VHL) may develop pancreatic neuroendocrine tumors (PNETs), which can behave in a malignant fashion. We prospectively evaluated size criteria for resection of lesions and the role of genotype/phenotype analysis of germline VHL mutations in predicting clinical course. Methods. From December 1988 through December 1999 we screened 389 patients with VHL. The diagnosis of PNET was made by pathologic analysis of tissues or by radiographic appearance. Germline mutations were determined by quantitative Southern blotting, fluorescence in situ hybridization and complete gene sequencing. Results. Forty-four patients with PNETs have been identified; 25 have undergone surgical resection, 5 had metastatic disease, and 14 are being monitored. No patient who has undergone resection based on tumor size criteria has developed metastases. Patients with PNETs were more likely to have missense mutations (58{\%}), and 4 of 5 patients (80{\%}) with metastatic disease had mutations in exon 3 compared with 18 of 39 (46{\%}) patients without metastatic disease. Conclusions. Imaging for detection and surgical resection based on size criteria have resulted in the successful management of VHL patients with PNETs. Analysis of germline mutations may help identifiy patients at risk for PNET and which patients may benefit from surgical intervention.",
author = "Libutti, {S. K.} and Choyke, {P. L.} and Alexander, {H. R.} and G. Glenn and Bartlett, {D. L.} and B. Zbar and I. Lubensky and McKee, {S. A.} and Maher, {E. R.} and Linehan, {W. M.} and Walther, {M. M.} and G. Akerstrom and J. Chabot",
year = "2000",
language = "English (US)",
volume = "128",
pages = "1022--1028",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease

AU - Libutti, S. K.

AU - Choyke, P. L.

AU - Alexander, H. R.

AU - Glenn, G.

AU - Bartlett, D. L.

AU - Zbar, B.

AU - Lubensky, I.

AU - McKee, S. A.

AU - Maher, E. R.

AU - Linehan, W. M.

AU - Walther, M. M.

AU - Akerstrom, G.

AU - Chabot, J.

PY - 2000

Y1 - 2000

N2 - Background. Patients with von Hippel-Lindau disease (VHL) may develop pancreatic neuroendocrine tumors (PNETs), which can behave in a malignant fashion. We prospectively evaluated size criteria for resection of lesions and the role of genotype/phenotype analysis of germline VHL mutations in predicting clinical course. Methods. From December 1988 through December 1999 we screened 389 patients with VHL. The diagnosis of PNET was made by pathologic analysis of tissues or by radiographic appearance. Germline mutations were determined by quantitative Southern blotting, fluorescence in situ hybridization and complete gene sequencing. Results. Forty-four patients with PNETs have been identified; 25 have undergone surgical resection, 5 had metastatic disease, and 14 are being monitored. No patient who has undergone resection based on tumor size criteria has developed metastases. Patients with PNETs were more likely to have missense mutations (58%), and 4 of 5 patients (80%) with metastatic disease had mutations in exon 3 compared with 18 of 39 (46%) patients without metastatic disease. Conclusions. Imaging for detection and surgical resection based on size criteria have resulted in the successful management of VHL patients with PNETs. Analysis of germline mutations may help identifiy patients at risk for PNET and which patients may benefit from surgical intervention.

AB - Background. Patients with von Hippel-Lindau disease (VHL) may develop pancreatic neuroendocrine tumors (PNETs), which can behave in a malignant fashion. We prospectively evaluated size criteria for resection of lesions and the role of genotype/phenotype analysis of germline VHL mutations in predicting clinical course. Methods. From December 1988 through December 1999 we screened 389 patients with VHL. The diagnosis of PNET was made by pathologic analysis of tissues or by radiographic appearance. Germline mutations were determined by quantitative Southern blotting, fluorescence in situ hybridization and complete gene sequencing. Results. Forty-four patients with PNETs have been identified; 25 have undergone surgical resection, 5 had metastatic disease, and 14 are being monitored. No patient who has undergone resection based on tumor size criteria has developed metastases. Patients with PNETs were more likely to have missense mutations (58%), and 4 of 5 patients (80%) with metastatic disease had mutations in exon 3 compared with 18 of 39 (46%) patients without metastatic disease. Conclusions. Imaging for detection and surgical resection based on size criteria have resulted in the successful management of VHL patients with PNETs. Analysis of germline mutations may help identifiy patients at risk for PNET and which patients may benefit from surgical intervention.

UR - http://www.scopus.com/inward/record.url?scp=20244363474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244363474&partnerID=8YFLogxK

M3 - Article

C2 - 11114638

AN - SCOPUS:20244363474

VL - 128

SP - 1022

EP - 1028

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 6

ER -